Author:
Milstein Meredith,Lecca Leonid,Peloquin Charles,Mitchison Denis,Seung Kwonjune,Pagano Marcello,Coleman David,Osso Elna,Coit Julia,Vargas Vasquez Dante Elmo,Sanchez Garavito Epifanio,Calderon Roger,Contreras Carmen,Davies Geraint,Mitnick Carole D.
Funder
National Institute of Allergy and Infectious Diseases
Publisher
Springer Science and Business Media LLC
Reference49 articles.
1. WHO. Global Tuberculosis Report 2015. Geneva, Switzerland: World Health Organization; 2015.
2. TB Alliance: Global Alliance for TB Drug Development. New TB Regimens: What Countries Want. 2009.
3. Owens JP, Fofana MO, Dowdy DW. Cost-effectiveness of novel first-line treatment regimens for tuberculosis. Int J Tuberc Lung Dis. 2013;17(5):590–6.
4. Johnson JL, Hadad DJ, Dietze R, Maciel EL, Sewali B, Gitta P, et al. Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med. 2009;180(6):558–63.
5. Dawson R, Diacon AH, Everitt D, van Niekerk C, Donald PR, Burger DA, et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet. 2015;385(9979):1738–47.
Cited by
32 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献